CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.
The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究解析了GPRC5D与单链可变片段(scFv)结合的结构,发现其跨膜螺旋4形成独特的同源二聚体界面。这些结构特征加深了对GPRC5D识别机制的认识,并为优化靶向GPRC5D的治疗策略提供了依据;GPRC5D是多发性骨髓瘤的重要治疗靶点。
GPRC5D is an atypical Class C orphan G protein-coupled receptor. Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for therapeutic interventions, including monoclonal antibodies, CAR-T cells, and T-cell engagers. Despite its therapeutic potential, the insufficient understanding regarding of the receptor's structure and antibody recognition mechanism has impeded the progress of effective therapeutic development.
Here, we present the structure of GPRC5D in complex with a preclinical-stage single-chain antibody (scFv).
Our structural analysis reveals that the GPRC5D presents a close resemblance to the typical Class C GPCRs in the transmembrane region.
We identify a distinct head-to-head homodimer arrangement and interface mainly involving TM4, setting it apart from other Class C homo- or hetero-dimers.
Furthermore, we elucidate the binding site engaging a sizable extracellular domain on GPRC5D for scFv recognition. These insights not only unveil the distinctive dimer organization of this unconventional Class C GPCR but also hold the potential to advance drug development targeting GPRC5D for the treatment of multiple myeloma.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。